Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for breast cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Breastcancer Autosynthesis - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search
Human Epidermal Growth Factor Receptor 2 (HER2) Testing in BreastCancer The CAP Website is Temporarily Unavailable The CAP Website is Currently Down for Scheduled Maintenance The CAP Website is currently unavailable due to scheduled maintenance on Saturday, July 14 between 5:00 AM - 4:00 PM (CT). We apologize for the inconvenience and appreciate your patience. For proficiency testing (Surveys) results , you can fax your results form to 866-FAX-2CAP (866-329-2227) or scan and email to . Contact
Change in longitudinal trends in sleep quality and duration following breastcancer diagnosis: results from the Womenâ€™s Health Initiative 29978034 2018 11 14 2374-4677 4 2018 NPJ breastcancer NPJ BreastCancer Change in longitudinal trends in sleep quality and duration following breastcancer diagnosis: results from the Women's Health Initiative. 15 10.1038/s41523-018-0065-7 Breastcancer survivors frequently report sleep problems, but little research has studied sleep patterns (...) longitudinally. We examined trends in sleep quality and duration up to 15 years before and 20 years after a diagnosis of breastcancer, over time among postmenopausal women participating in the Women's Health Initiative (WHI). We included 12,098 participants who developed invasive breastcancer after study enrollment. A linear mixed-effects model was used to determine whether the time trend in sleep quality, as measured by the WHI Insomnia Rating Scale (WHIIRS), a measure of perceived insomnia symptoms from
Using interferon-beta to combat cancer stem cell properties in triple negative breastcancer 30035180 2018 11 14 2331-4737 5 5-6 2018 May Oncoscience Oncoscience Using interferon-beta to combat cancer stem cell properties in triple negative breastcancer. 169-171 10.18632/oncoscience.438 Doherty Mary R MR Department of Pathology, Case Western Reserve University, School of Medicine, Cleveland, OH 44106, USA; bCase Comprehensive Cancer Center, Case Western Reserve University, School of Medicine (...) , Cleveland, OH 44106, USA. Jackson Mark W MW Department of Pathology, Case Western Reserve University, School of Medicine, Cleveland, OH 44106, USA; bCase Comprehensive Cancer Center, Case Western Reserve University, School of Medicine, Cleveland, OH 44106, USA. eng R21 CA198808 CA NCI NIH HHS United States Editorial 2018 06 28 United States Oncoscience 101636666 2331-4737 cancer stem cells cellular plasticity interferon-beta triple-negative breastcancer CONFLICTS OF INTEREST The authors declare
Targeting Cdk5 for killing of breastcancer cells via perturbation of redox homeostasis 30035173 2018 11 14 2331-4737 5 5-6 2018 May Oncoscience Oncoscience Targeting Cdk5 for killing of breastcancer cells via perturbation of redox homeostasis. 152-154 10.18632/oncoscience.431 NavaneethaKrishnan Saranya S Department of Cell Biology and Anatomy, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada. Rosales Jesusa L JL Department of Cell Biology and Anatomy, Arnie (...) Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada. Lee Ki-Young KY Department of Cell Biology and Anatomy, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada. eng Editorial 2018 06 27 United States Oncoscience 101636666 2331-4737 Cdk5 ROS breastcancer phosphorylation protein kinase CONFLICTS OF INTEREST The authors declare that they have no competing interests. 2018 05 05 2018 05 09 2018 7 24 6 0 2018 7 24 6 0 2018 7 24 6 1 epublish 30035173 10.18632
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastaticbreastcancer 29951582 2018 11 14 2374-4677 4 2018 NPJ breastcancer NPJ BreastCancer Cdk4/6 inhibitors and overall survival: power of first-line trials in metastaticbreastcancer. 14 10.1038/s41523-018-0068-4 Palbociclib, ribociclib, and abemaciclib have been investigated in combination with aromatase inhibitors as first-line therapy for metastatic hormone receptor-positive breastcancer (PALOMA-2, MONALEESA-2 (...) Alexia A 1Department of Biometry, Institut Curie, PSL Research University, Saint Cloud, France. grid.440907.e Bidard Francois-Clement FC 0000-0001-5932-8949 2Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France. grid.440907.e UVSQ, Paris Saclay University, Saint Quentin en Yvelines, Paris, France. eng Journal Article Review 2018 06 26 United States NPJ BreastCancer 101674891 2374-4677 F.-C. Bidard is part of advisory boards and received research grants (unrelated
TP53 protein levels, RNA-based pathway assessment, and race among invasive breastcancer cases 29951581 2018 11 14 2374-4677 4 2018 NPJ breastcancer NPJ BreastCancer TP53 protein levels, RNA-based pathway assessment, and race among invasive breastcancer cases. 13 10.1038/s41523-018-0067-5 Mutations in tumor suppressor TP53 have been inconsistently linked to breastcancer risk factors and survival. Immunohistochemistry (IHC) staining, a primary clinical means of TP53 mutation determination (...) , only detects mutations that facilitate protein accumulation (e.g., missense mutations). RNA-based pathway methods capture functional status and may aid in understanding the role of TP53 function in racial disparities of breastcancer. TP53 status was assessed among invasive breastcancer cases from the Carolina BreastCancer Study (CBCS) (2008-2013) using IHC and an established RNA-based TP53 signature (CBCS and The Cancer Genome Atlas (TCGA)). Frequency of TP53 status (IHC, RNA-based
Targeting p27 tyrosine phosphorylation as a modality to inhibit CDK4 and CDK2 and cause cell cycle arrest in breastcancer cells 30035169 2018 11 14 2331-4737 5 5-6 2018 May Oncoscience Oncoscience Targeting p27 tyrosine phosphorylation as a modality to inhibit CDK4 and CDK2 and cause cell cycle arrest in breastcancer cells. 144-145 10.18632/oncoscience.427 Blain Stacy W SW Departments of Cell Biology and Pediatrics, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA. eng Editorial 2018 06 (...) 25 United States Oncoscience 101636666 2331-4737 breastcancer cdk2 cdk4 p27Kip1 palbociclib CONFLICTS OF INTEREST S.W. Blain has ownership interest (including patents) in Concarlo Holdings, LLC and is a consultant/advisory board member for Concarlo Holdings, LLC. 2018 05 09 2018 05 11 2018 7 24 6 0 2018 7 24 6 0 2018 7 24 6 1 epublish 30035169 10.18632/oncoscience.427 427 PMC6049303 Cancer Res. 2016 Apr 15;76(8):2301-13 27020857 Cancer Discov. 2016 Apr;6(4):353-67 26658964 Cell Cycle. 2008 Apr
Targeting MYC for triple-negative breastcancer treatment 30035158 2018 11 14 2331-4737 5 5-6 2018 May Oncoscience Oncoscience Targeting MYC for triple-negative breastcancer treatment. 120-121 10.18632/oncoscience.414 Klauber-DeMore Nancy N Developmental Cancer Therapeutics (DCT) Program, Hollings Cancer Center; Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC 29425, USA. Schulte Bradley A BA Developmental Cancer Therapeutics (DCT) Program (...) cancer stem cells triple-negative breastcancers (TNBC) triptolide CONFLICTS OF INTEREST The authors declare no potential conflicts of interest. 2018 04 23 2018 04 25 2018 7 24 6 0 2018 7 24 6 0 2018 7 24 6 1 epublish 30035158 10.18632/oncoscience.414 414 PMC6049315 Cell Metab. 2017 Oct 3;26(4):633-647.e7 28978427 Cancer Res. 2015 Mar 15;75(6):924-9 25604264 Cancer Res. 2017 Dec 1;77(23):6641-6650 28951456 Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13028-33 17664422 Cell. 2011 Sep 16;146(6):904-17
siRNAs Targeting Growth Factor Receptor and Anti-Apoptotic Genes Synergistically Kill BreastCancer Cells through Inhibition of MAPK and PI-3 Kinase Pathways 29932151 2018 11 14 2227-9059 6 3 2018 Jun 22 Biomedicines Biomedicines siRNAs Targeting Growth Factor Receptor and Anti-Apoptotic Genes Synergistically Kill BreastCancer Cells through Inhibition of MAPK and PI-3 Kinase Pathways. E73 10.3390/biomedicines6030073 Breastcancer, the second leading cause of female deaths worldwide, is usually (...) . Since siRNAs demonstrate limited cell permeability and unfavorable pharmacokinetic behaviors, pH-sensitive nanoparticles of carbonate apatite were employed to efficiently carry the siRNAs in vitro and in vivo. By delivering selective siRNAs against the mRNA transcripts of the growth factor receptors, such as ER, ERBB2 (HER2), EGFR and IGFR, and anti-apoptotic protein, such as BCL2 in human (MCF-7 and MDA-MB-231) and murine (4T1) breastcancer cell lines, we found that ESR1 along with BCL-2
Assessment and Improvement Strategies for a BreastCancer Early Detection Program in Rural South Africa 30085890 2018 12 07 2378-9506 4 2018 Jul Journal of global oncology J Glob Oncol Assessment and Improvement Strategies for a BreastCancer Early Detection Program in Rural South Africa. 1-12 10.1200/JGO.18.00015 Purpose To assess and develop solutions for an ultrasound-based breastcancer early detection program in rural South Africa 1 year after implementation. Methods A WHO-endorsed RAD-AID (...) that the documentation system is easy and useful and improves overall quality of care, follow-up, decision making; access to clinical information; and communication between clinicians and patients. Five of the seven providers reported that the system increased visit time, but three of those five believed that the process was valuable. Conclusion Implementation of a breastcancer early detection program in resource-limited regions is challenging, and continual assessment is essential. As a result of identified needs
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastaticbreastcancer: a systematic review and meta-analysis 29942664 2018 11 14 2059-7029 3 4 2018 ESMO open ESMO Open Single-agent PARP inhibitors for the treatment of patients with BRCA -mutated HER2-negative metastaticbreastcancer: a systematic review and meta-analysis. e000361 10.1136/esmoopen-2018-000361 Single-agent poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have been approved (...) as the first targeted therapy available for patients with BRCA -mutated HER2-negative metastaticbreastcancer. This meta-analysis aimed to better evaluate activity, efficacy and safety of single-agent PARPi in this population. A systematic search of Medline, Embase and conference proceedings up to 31 January 2018 was conducted to identify randomised controlled trials (RCTs) investigating single-agent PARPi versus monochemotherapy in patients with BRCA -mutated HER2-negative metastaticbreastcancer. Using
Definitive hypofractionated radiation therapy for early stage breastcancer: Dosimetric feasibility of stereotactic ablative radiotherapy and proton beam therapy for intact breasttumors 30202812 2018 11 14 2452-1094 3 3 2018 Jul-Sep Advances in radiation oncology Adv Radiat Oncol Definitive hypofractionated radiation therapy for early stage breastcancer: Dosimetric feasibility of stereotactic ablative radiotherapy and proton beam therapy for intact breasttumors. 447-457 10.1016/j.adro (...) .2018.05.002 Few definitive treatment options exist for elderly patients diagnosed with early stage breastcancer who are medically inoperable or refuse surgery. Historical data suggest very poor local control with hormone therapy alone. We examined the dosimetric feasibility of hypofractionated radiation therapy using stereotactic ablative radiotherapy (SABR) and proton beam therapy (PBT) as a means of definitive treatment for early stage breastcancer. Fifteen patients with biopsy-proven early stage
Are Global BreastCancer Incidence and Mortality Patterns Related to Country-Specific Economic Development and Prevention Strategies? 30085889 2018 12 07 2378-9506 4 2018 Jul Journal of global oncology J Glob Oncol Are Global BreastCancer Incidence and Mortality Patterns Related to Country-Specific Economic Development and Prevention Strategies? 1-16 10.1200/JGO.17.00207 Purpose There remains considerable international variation in breastcancer incidence and mortality, but a comprehensive (...) examination of rates by country level economic, development and cancer prevention policies is lacking. Materials and Methods We compared GLOBOCAN 2012 age-specific breastcancer incidence and mortality rates for 177 countries by using development and policy data available from the WHO Global Cancer Country Profiles data base. We classified each country on the basis of gross national income per capita from the World Development Indicators data base, as follows: low-income country (LIC), lower-middle-income
Axillary lymph node metastasis detection by magnetic resonance imaging in patients with breastcancer: A metaâ€analysis 29877048 2018 11 14 1759-7714 9 8 2018 Aug Thoracic cancer Thorac Cancer Axillary lymph node metastasis detection by magnetic resonance imaging in patients with breastcancer: A meta-analysis. 989-996 10.1111/1759-7714.12774 The study was conducted to evaluate the diagnostic performance of magnetic resonance imaging (MRI) for the detection of axillary lymph node metastasis (...) in patients with breastcancer. PubMed, Medline, Web of Science, Cochrane Embase, Chinese Biomedical Literature, and China National Knowledge Infrastructure databases were searched for open published studies relevant to the use of MRI for the detection of axillary lymph node metastasis in breastcancer patients. The pooled diagnostic sensitivity, specificity, and the symmetric receiver operating characteristic (SROC) curve was calculated by combining the individual data extracted from 26 included studies
Tailoring Adjuvant Endocrine Therapy for Premenopausal BreastCancer. Background In the Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen and Exemestane Trial (TEXT), the 5-year rates of recurrence of breastcancer were significantly lower among premenopausal women who received the aromatase inhibitor exemestane plus ovarian suppression than among those who received tamoxifen plus ovarian suppression. The addition of ovarian suppression to tamoxifen did not result in significantly (...) % of the exemestane-ovarian suppression group. Conclusions Among premenopausal women with breastcancer, the addition of ovarian suppression to tamoxifen resulted in significantly higher 8-year rates of both disease-free and overall survival than tamoxifen alone. The use of exemestane plus ovarian suppression resulted in even higher rates of freedom from recurrence. The frequency of adverse events was higher in the two groups that received ovarian suppression than in the tamoxifen-alone group. (Funded by Pfizer
Panoptic Overview of Triple-Negative BreastCancer in Nigeria: Current Challenges and Promising Global Initiatives 30085829 2018 12 07 2378-9506 4 2018 Jul Journal of global oncology J Glob Oncol Panoptic Overview of Triple-Negative BreastCancer in Nigeria: Current Challenges and Promising Global Initiatives. 1-20 10.1200/JGO.17.00116 Purpose Triple-negative breastcancer (TNBC) is the most deadly form of breastcancer (BC) today. TNBC treatment is fraught with challenges because (...) PMC6223531 BreastCancer Res Treat. 2017 May;163(1):151-158 28213780 Glob Health Promot. 2015 Jun;22(2):31-9 25027971 PLoS One. 2017 Feb 13;12(2):e0171024 28192444 J Glob Oncol. 2016 Apr 6;2(6):397-402 28717726 BreastCancer Res Treat. 2012 Aug;135(1):59-66 22527102 J Clin Oncol. 2009 Sep 20;27(27):4515-21 19704069 BMC Cancer. 2008 Oct 23;8:307 18947390 Afr Health Sci. 2011 Jun;11(2):279-84 21857862 Front Biosci (Landmark Ed). 2017 Jun 1;22:1549-1580 28410132 BMC Cancer. 2009 Jun 25;9:203 19555506 Ann
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in BreastCancer. Background The recurrence score based on the 21-gene breastcancer assay predicts chemotherapy benefit if it is high and a low risk of recurrence in the absence of chemotherapy if it is low; however, there is uncertainty about the benefit of chemotherapy for most patients, who have a midrange score. Methods We performed a prospective trial involving 10,273 women with hormone-receptor-positive, human epidermal growth (...) factor receptor 2 (HER2)-negative, axillary node-negative breastcancer. Of the 9719 eligible patients with follow-up information, 6711 (69%) had a midrange recurrence score of 11 to 25 and were randomly assigned to receive either chemoendocrine therapy or endocrine therapy alone. The trial was designed to show noninferiority of endocrine therapy alone for invasive disease-free survival (defined as freedom from invasive disease recurrence, second primary cancer, or death). Results Endocrine therapy